The value of serum IL-4 to predict the survival of MDS patients
Zhaoyun Liu1, Xintong Xu1, Likun Zheng1
1Department of Hematology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Background:
Immune indicators are routinely used for the detection of myelodysplastic syndrome (MDS), but these are not utilized as a reference indicator to assess prognosis in MDS-related prognostic evaluation systems, such as the World Health Organizational prognostic scoring system, the international prostate symptom score, and the revised international prostate symptom score.
Methods:
We examined immune indicators, including cluster of differentiation (CD)3, CD4, CD8, CD56, CD19, interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor-a, and interferon-γ in 155 newly diagnosed MDS patients. We also conducted a correlation analysis with clinical indices.
Results:
IL-4 was found to be a predictor of survival in these 155 patients using the receiver operating characteristic curve, with 5.155 as the cut-off point. Patients with serum IL-4 levels ≥ 5.155 had a lower overall survival (OS) than those with IL-45.155 at diagnosis. Furthermore, multivariate analysis revealed that IL-4 levels > 5.155 were an independent predictor of OS (hazard ratio: 0.237; 95% confidence interval, 0.114-0.779; P = 0.013). In addition, serum IL-4 expression in the three different scoring systems showed significant differences in the survival of medium- to high-risk MDS patients (P = 0.014, P < 0.001, P < 0.001).
Conclusions:
According to our study, IL-4 levels at the time of diagnosis can predict MDS prognosis in patients as a simple index reflecting host systemic immunity.
Insights
Interleukin-4 (IL-4) levels at diagnosis predict myelodysplastic syndrome (MDS) prognosis. Higher IL-4 indicates lower overall survival, serving as a simple index of systemic immunity for MDS patients.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Immune indicators are vital for detecting myelodysplastic syndrome (MDS).
- Current prognostic systems for MDS do not routinely incorporate immune indicators.
- Existing systems include the World Health Organization prognostic scoring system and international prostate symptom scores.
Purpose of the Study:
- To investigate the prognostic value of immune indicators in myelodysplastic syndrome (MDS).
- To determine if specific immune markers can predict overall survival in MDS patients.
- To explore the correlation between immune markers and clinical indices in MDS.
Main Methods:
- Examined 155 newly diagnosed MDS patients.
- Assessed immune indicators: cluster of differentiation (CD)3, CD4, CD8, CD56, CD19, interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor-alpha, and interferon-gamma.
- Conducted correlation analysis with clinical indices and survival data.
Main Results:
- Interleukin-4 (IL-4) was identified as a survival predictor in MDS patients (cut-off: 5.155).
- Patients with IL-4 levels ≥ 5.155 showed significantly lower overall survival (OS).
- Multivariate analysis confirmed IL-4 > 5.155 as an independent predictor of OS (HR: 0.237; P=0.013).
Conclusions:
- Serum IL-4 levels at diagnosis can predict MDS prognosis.
- IL-4 serves as a simple index reflecting host systemic immunity.
- IL-4 expression significantly impacts survival in medium- to high-risk MDS patients.
